Therapy of chronic hepatitis C in the setting of HIV co-infection

Acta Gastro-Enterologica Belgica

Volumn 68, Issue 1, 2005, Pages 86-91

  Michielsen, P ^a   Bottieau, E ^b  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b INSTITUTE OF TROPICAL MEDICINE   (Belgium)

Author keywords

Antiretroviral therapy; Co infection; Hepatitis C; Human immunodeficiency virus; Interferon; Pegylated interferon; Ribavirin

Indexed keywords

ABACAVIR; ALCOHOL; ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; DNA POLYMERASE; GUANOSINE DERIVATIVE; INDINAVIR; LIVER ENZYME; NEVIRAPINE; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PROTEINASE INHIBITOR; RIBAVIRIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; CLINICAL FEATURE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE COURSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; FATTY LIVER; FEVER; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; HYPERSENSITIVITY REACTION; IMPAIRED GLUCOSE TOLERANCE; INTRAVENOUS DRUG ABUSE; LACTIC ACIDOSIS; LEUKOCYTE COUNT; LEUKOPENIA; LIVER CIRRHOSIS; LIVER TOXICITY; METABOLIC DISORDER; MITOCHONDRIAL TOXICITY; NEUROPATHY; OUTCOMES RESEARCH; PANCREATITIS; PHOSPHORYLATION; PRACTICE GUIDELINE; PREDICTION; RASH; RISK FACTOR; SUPERINFECTION; SURVIVAL RATE; VIRUS LOAD; VIRUS TRANSMISSION;

ADOLESCENT; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; COMORBIDITY; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; RIBAVIRIN; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 16444369772     PISSN: 00015644     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (76)

1. World Health Organisation Weekly Epidemiological Record 49, 1999.
2. World Health Organisation; AIDS epidemic update: December 2003.
3. CARDO D.M., CULVER D.H., CIESIELSKI C.A., SRIVASTAVA P.U., MARCUS R., ABITEBALL D. et al. Case control study of a HIV-sero-conversion in health care workers after percutaneous exposure. N. Engl. J. Med., 1997, 337: 1485-1490.
4. CDC. Prevalence of hepatitis C virus infection among clients of HIV counseling and testing sites - Connecticut, 1999. MMWR. 1999 (50), 27: 577-581.
5. THOMAS D.L.S.J., ALTER H.J., VLAKOV D., COHN S., HOOVER D.R., CHEUNG L., NELSON K.E. Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users. J. Infect. Dis., 1996, 174: 690-895.
6. STUBBE L., SORIANO V., ANTUNES F. et al. Hepatitis C in the Euro SIDA cohort of European HIV-infected patients. Prevalence and prognostic value (abstract 22261). Conference record of the 12th World AIDS Conference, Geneva, Switzerland. Geneva, Marathon Multimedia, 1998.
7. BICA I., MC GOVERN B., DHAR R., STONE D., MC GOWAN K., SCHEIB R., SNYDMAN D.R. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin. Infect. Dis., 2001, 32: 492-497.
8. CACOUB P., GEFFRAY L., ROSENTHAL E., PERRONNE C., VEYSSIER P., RAGUIN G., Joint Study Group on Hepatitis C Virus of the French National Society of Internal Medicine and the French Society of Infectious Diseases (GERMVIC Study Group). Mortality among HIV-infected patients with cirrhosis or hepatocellular carcinoma due to hepatitis C virus in French Departments of Internal Medicine/Infectious Diseases in 1995 and 1997. Clin. Infect. Dis., 2001, 32: 107-1214.
9. ROSENTHAL E., POIRÉE M., PRADIER C., PERRONNE C., SALMON-CERON D., GEFFRAY L., MYERS R.P., MORLAT P., PIALOUX G., POL S., CACOUB P., GERMIVIC JOINT STUDY GROUP. Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic, 2001 study). AIDS, 2003, 17: 1803-1807.
10. SATO B, SÁNCHEZ-QUIJANO A., RODRIGO L., DEL OLMO J.A., GARCIA-BENGOECHEA M., HERNANDEZ-QUERO J., REY C., ABAD M.A., RODRIGUEZ M., SALES GILABERT M., GONZALEZ F., MIRON P., CARUZ A., RELIMPIO F., TORRONTERAS R., LEAL M., LISSEN E. Impact of HIV type 1 infection on the natural course of chronic parenterally acquired hepatitis C with an unusually rapid progression to cirrhosis. J. Hepatol., 1997, 26: 1-5.
11. SÁNCHEZ-QUIJANO A., ANDREU J., GAVILAN F., LUQUE F., ABAD M.A., SOTO B., MUNOZ J., AZNAR J.M., LEAL M., LISSEN E. Influence of HIV type 1 infection on the natural course of chronic parenterally acquired hepatitis C. Eur. J. Clin. Microbiol. Infec. Dis., 1995, 14: 949-953.
12. BENHAMOU Y.B.M., DI MARTINO V., CHARLOTTE F., AZIRIA F., COUTELHER A., VIDAD M., BRICAIRE F., OPDON P., KATHAMA C., POYNARD T. Liver fibrosis progression and hepatitis C virus co-infected patients. Hepatology, 1999, 30: 1054-1058.
13. GARCÍA-SAMANIEGO J., RODRÍGUEZ M., BERENGUER J., RODRÍGUEZ-ROSADO R., CARBÓ J., ASENSI V., SORIANO V. Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am. J. Gastroenterol., 2001, 96: 179-183.
14. QURISHI N., KREUZBERG C., LÜCHTERS G., EFFENBERGER W., KUPFER B., SAUERBRUCH T., ROCKSTROH J.K., SPENGLER U. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet, 2003, 362: 1708-13.
15. LEIN M.B., LALONDE R.G., SUISSA S. The impact of Hepatitis C virus coinfection on HIV progression before and after Highly Active Antiretroviral Therapy. J. Acq. Imm. Def. Syndr., 2003, 33: 365-372.
16. DORRUCCI M., PEZZOTTI P., PHILLIPS A.N., LEPRI A.C., REZZA G. Coinfection of hepatitis C virus with human immunodeficiency virus and progression to AIDS. J. Infect. Dis., 1995, 172: 1503-1508.
17. STAPLES C.T., RIMBAUD D., DUDAS D. Hepatitis C in the the HIV (Human Immunodeficiency Virus) Atlanta VA (Veterans Affairs Medical Center) Cohort Study (HAVACS): The effect of coinfection on survival. Clin. Infect. Dis., 1999, 29: 150-154.
18. WRIGHT T.L., HOLLANDER H., PU X., HELD M.J., LIPSON P., QUAN S., POLITO A., THALER M.M., BACCHETTI P., SCHARSCHMIDT B.F. Hepatitis C in HIV-infected patients with and without AIDS : prevalence and relationship to patient survival. Hepatology, 1994, 20: 1152-1155.
19. PIROTH L., DUONG M., QUANTIN C. Does HCV co-infection accelerate clinical and immunological evolution of HIV-infected patients? AIDS, 1998, 12: 381-388.
20. SABIN C., TELFER P., PHILIPS A., BHAGANI S., LEE C. The association between HCV genotype and HIV disease progression in a cohort of hemophiliacs. J. Infect. Dis., 1997, 175: 164-168.
21. LESENS O., DESCHENES M., STEBEN M., BELANGER G., TSOUKS C. Hepatitis C virus is relate to progessive liver disease in HIV-positive hemopiliacs and should be treated as an opportunistic infection. J. Infect. Dis., 1999, 179: 1254-1258.
22. TEDALDI E.M., BAKER R.K., MOORMAN A.C., ALZOLA C.F., FURHRER J., McCABE R.E., WOOD K.C., HOLMBERG S.D., HIV OUTPATIENT STUDY (HOPS) INVESTIGATORS. Influence of coinfection with HCV on morbidity and mortality due to HIV infection in the era of HAART. Clin. Infect. Dis., 2003, 36: 363-367.
23. GREUB G., LEDERGERBER B., BATTEGAY M., GROB P., PERRIN L., FURRER H., BURGISSER P., ERB P., BOGGIAN K., PIFFARETTI J.C., HIRSCHEL B., JANIN P., FRANCIOLI P., FLEPP M., TELENTI A. Clinical progression and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection. Lancet, 2000, 336: 1800-1805.
24. SORIANO V., MARTIN J.C., GONZÁLEZ-LAHOZ J. HIV-1 progression in hepatitis C-infected drug users. Lancet, 2001, 357: 1361-1362.
25. DE LUCA A., BUGARINI R., LEPRI A. Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naïve HIV-infected subjects. Arch. Intern. Med., 2000, 162: 2125-2132.
26. SULKOWSKI M., MOORE R., MEHTA S., CHAISSON R., THOMAS D. Hepatitis C and progression of HIV disease. JAMA, 2002, 288: 199-206.
27. LINCOLN D., PETOUMENOS K., DORE G.J., Australian HIV Observational Database. HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy. HIV Med., 2003, 4: 241-249.
28. MACIAS J., MELGUIZO I., FERNANDEZ-RIVERA F. Mortality due to liver failure and impact on survival of hepatitis virus infections in HIV-infected patients receiving potent antiretroviral therapy. Eur. J. Clin. Microbiol. Infect. Dis., 2002, 21: 775-781.
29. DEN BRINKER M., WIT F., WERTHEIM-VAN DILLEN P. Hepatitis B and hepatitis C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS, 2000, 14: 2895-2902.
30. SULKOWSKI M., THOMAS D., CHAISSON R., MOORE R. Hepatotoxicity associated with antiretroviral therapy in adults infected with HIV and the role of hepatitis C or B virus infection. JAMA, 2000, 283: 74-80.
31. SORIANO V., MIRO J.M., GARCIA-SAMANIEGO J., TORRE-CISNEROS J., NUNEZ M. et al. Consensus conference on chronic viral hepatitis and HIV infection: updated Spanish recommendations. J. Viral Hep., 2004, 11: 2-17.
32. SULKOWSKI M., THOMAS D., MEHTA S., CHAISSON R., MOORE R. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology, 2002, 35: 182-189.
33. SAVES M., VANDENTORREN S., DAUCOURT V. Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine Cohort, France 1996-1998. AIDS, 1999, 13: F115-F121.
34. WIT F., WEVERLING G., WEEL J., JURRIANS S., LANGE J. Incidence and risk factors for severe hepatotoxicity associated with antireroviral combination therapy. J. infect. Dis., 2002, 186: 23-31.
35. JOHN M., FLEXMAR J., FRENCH M. Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease? AIDS, 1998, 12: 2289-2293.
36. PUOTI M., TORTI C., RIPAMONTI D., CASTELLI F., ZALTRON S., GROB P., PERRIN L., FURRER H., BURGISSER P., ERB P., BOGGIAN K., PIFFARETTI J.C., HIRSCHEL B., JANIN P., FRANCIOLI P., FLEPP M., TELENTI A. Severe hepatotoxicity during combination antiretroviral treatment: incidence, liver histology, and outcome. J. AIDS, 2003, 32: 259-267.
37. POL S., TRINH THI N., THIERS V., JAFFREDO F., CARNOT F., LAMORTHE B., ZYLBERBERG H., BERTHELOT P., BRECHOT C., NALPAS B. Chronic hepatitis C of drug users: influence of HIV-infection. Hepatology, 1995, 22: 340A.
38. MARRIOTT E., NAVAS S., DEL ROMERO J., GARCIA S., CASTILLO I., QUIROGA J.A., CARRENO V. Treatment with recombinant alfa-interferon of chronic hepatitis C in ani-HIV-positive patients. J. Med. Virol., 1993, 40: 107-111.
39. SORIANO V., GARCÍA-SAMANIEGO J., BRAVO R., GONZALEZ J., CASTRO A., CASTILLA J., MARTINEZ-ODRIOZOLA P., COLMENERO M., CARBALLO E., SUAREZ D., RODRIGUEZ-PINERO F.J., MORENO A., DEL ROMERO J., PEDREIRA J., GONZALEZ-LAHOZ J. Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Clin. Infect. Dis., 1996, 23: 585-691.
40. BOYER N., MARCELLIN P., DEGOTT C., DEGOS F., SAIMOT A.G., ERLINGER S., BENHAMOU J.P. Recombinant interferon-alpha for chronic hepatitis C in patients positive for antibody to HIV. J. Infect. Dis., 1992, 165: 723-726.
41. MARCELLIN P., MARTINOT-PEIGNOUX M., ELIAS A., BRANGER M., COURTOIS F., LEVEL R., ERLINGER S., BENHAMOU J.P. HCV viremia in HIV-seronegative and seropositive patients with indeterminate HCV recombinant immunoblot assay. J. Infect. Dis., 1994, 170: 933-935.
42. MAUSS S., KLINKER H., ULMER A., WILLERS R., WEISSBRICH B., ALBRECHT H., HAUSSINGER D., JABLONOWSKI H. Response to treatment of chronic hepatitis C with interferon alpha in patients infected with HIV-1 is associated with higher CD4+ cell count. Infection, 1998, 26: 16-19.
43. CAUSSE X., PAYEN J., IZOPET J., BABANY G., GIRARDIN M. Does HIV infection influence the response of chronic hepatitis C to interferon treatment? J. Hepatol., 2000, 1003-1010.
44. PRESTILEO T., MAZZOLA G., DI LORENZO F., COLLETTI P., VITALE F., FERRARO D., DI STEFANO R., CAMMA C., CRAXI A. Response-adjusted alpha-interferon therapy for chronic hepatitis C in HIV-infected patients. Int. J. Antimicrob. Agents, 2000, 16: 373-378.
45. VENTO S., DI PERRI G., CRUCIANI M., GAROFANO T., CONCIA E., BASSETTI D. Rapid decline of CD4+ cells after interferon alpha treatment in HIV-1 infection. Lancet, 1993, 341: 958-959.
46. CALLENS S., BOTTIEAU E., MICHIELSEN P., COLEBUNDERS R. Pegylated interferon alpha-2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS, 2004, 18: 131 (letter).
47. SORIANO V., BRAVO R., GARCÍA-SAMANIEGO J., et al. CD4+ T-lymphopenia in HIV-infected patients receiving interferon therapy for chronic hepatitis C. AIDS, 1994, 8: 1621-1622.
48. SORIANO V., GARCÍA-SAMANIEGO J., RODRIGUEZ-ROSADO R., GONZALEZ J., PEDREIRA J. Hepatitis C and HIV infection: biological, clinical and therapeutic implications. J. Hepatol. 1999, 31 (Suppl. 1): 119-123.
49. McHUTCHISON J.G., GORDON S.C., SCHIFF E.R., SHIFFMAN M.L., LEE W.M., RUSTGI V.K., GOODMAN Z.D., LING M.-H., CORT S., ALBRECHT J.K., HEPATITIS INTERVENTIONAL THERAPY GROUP. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N. Engl J. Med., 1998, 339: 1485-1492.
50. POYNARD T., MARCELLIN P., LEE S.S., NIEDERAU C., MINUK G.S., IDEO G., BAIN V., HEATHCOTE J., ZEUZEM S., TREPO C., ALBRECHT J., INTERNATIONAL HEPATITIS INTERVENTIONAL THERAPY GROUP. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for treatment of chronic infection with hepatitis C virus. Lancet, 1998, 352: 1426-1432.
51. PÉREZ-OLMEDA M., GONZÁLEZ J., GARCÍA-SAMANIEGO J., ARRIBAS J., PEÑA J., SORIANO V. Interferon plus ribavirin in HIV-infected patients with chronic hepatitis C. J. AIDS, 1999, 22: 308-309.
52. ZYLBERBERG H., BENHAMOU Y., LAGNEAU J.L., LANDAU A., CHAIX M.-L., FONTAINE H., BUCHET M., POYNARD T., KATLAMA C., PIALOUX G., BRÉCHOT C., POL S. Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report. Gut. 2000, 47: 694-697.
53. LANDAU A., BATISSE D., PIKETTY C., DUONG VAN HUYEN J.P., BLOCH F., BELEC L., BRUNEVAL P., WEISS L., JIAN R., KAZATCHKINE M.D. Long-term efficacy of combination therapy with interferon alpha-2b and ribavirin for severe chronic hepatitis C in HIV-infected patients. AIDS, 2001, 15: 1149-1155.
54. SAULEDA S., JUÁREZ A., ESTEBAN J.I., ALTISENT C., RUIZ I., PUIG L., ESTEBAN R., GUARDIA J. Interferon and ribavirin combination therapy for chronic hepatitis C in human immunodeficiency virus-infected patients with congenital coagulation disorders. Hepatology, 2001, 34: 1035-1040.
55. NASTI G., DI GENNARO G., TAVIO M., CADORIN L., TEDESCHI R.M., TALAMINI R., CARBONE A., TIRELLI U. Chronic hepatitis C in HIV infection: feasibility and sustained efficacy of therapy with interferon-alfa-2b and ribavirin. AIDS, 2001, 15: 1783-1787.
56. BOCHET M., DE TORRES M., VALANTAN M. et al. Efficacy and tolerance of interferon plus ribavirin for chronic hepatitis C in HIV-infected patients. 8th CROI 2001, Chicago, Abstract 574.
57. PÉREZ-OLMEDA M., SORIANO V., ASENSI V., MORALES D., ROMERO M., OCHOA, SANCHEZ-MONTERO F., SANTIN M., GUARDIOLA J., BLANCH J., NUNEZ M., JIMENEZ, NACHER I., GÁRCIA-SAMANIEGO J., The HCV/HIV Spanish Study Group. Treatment of chronic hepatitis C in HIV-infected patients with interferon alpha-2b plus ribavirin. AIDS Res. Hum. Retroviruses, 2003, 19: 1083-1089.
58. VOGT M.W., HARTSHORN K.L., FURMAN P.A., CHOU T.C., FYFE J.A., COLEMAN L.A., CRUMPACKER C., SCHOOLEY R.T., HIRSCH M.S. Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science, 1987, 235: 1376-1379.
59. MORSICA G., DE BONA A., UBERTI C., SITIA G., FINAZZI R., LAZZARIN A. Ribavirin therapy for chronic hepatitis C in HIV-infected patients. AIDS, 2000, 14: 1656-1658.
60. LANDAU A., BATISSE D., PIKETTY C., JIAN R., KAZATCHKTNE M. Lack of interference between ribavirin and nucleoside analogues in HIV/HCV coinfected individuals undergoing concomitant anti-retroviral and anti-HCV combination therapy. AIDS, 2000, 14: 1857-1858.
61. LAFEUILLADE A., HITTINGER G., CHAPAUDAUD S. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet, 2001, 357: 1803.
62. KAKUDA T., BRINKMAN K. Mitochondrial toxic effects of ribavirin. Lancet, 2001, 357: 1802-1803.
63. SALMON-CÉRON D., CHAUVELOT-MOACHON J., ABAC S., SILBERMANN B., SOGNI P. Mitochondrial toxic effects of ribavirin. Lancet, 2001, 357: 1803.
64. MANNS M.P., McHUTCHISON J.G., GORDON S.C., RUSTGI V.K., SHIFFMAN M., REINDOLLAR R., GOODMAN Z.D., KOURY K., LING M.-H., ALBRECHT J.K., INTERNATIONAL HEPATITIS INTERVENTIONAL THERAPY GROUP. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet, 2001, 358: 958-965.
65. FRIED M.W., SHIFFMAN M., REDDY K.R., SMITH C., MARINOS G., GONÇALEZ F.R. Jr., HÄUSSINGER D., DIAGO M., CAROSI G., DHUMEAUX D., CRAXÍ A., LIN A., HOFFMAN J., YU J., Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med., 2002, 347: 975-982.
66. HADZIYANNIS S.J., SETTE H. Jr., MORGAN T.R., BALAN V., DIAGO M., MARCELLIN P., RAMADORI G., BODENHEIMER H. Jr., BERNSTEIN D., RIZZETTO M., ZEUZEM S., POCKROS P.J., LIN A., ACKRILL A.M., PEGASYS INTERNATIONAL STUDY GROUP. Peginterferon alfa-2a and ribavirin combination treatment in chronic hepatitis C: randomized study of the effect of treatment duration and ribavirin dose. Ann. Intern. Med., 2004, 140: 346-355.
67. PEŹREZ-OLMEDA M., NUNEZ M., ROMERO M., GONZALEZ J., CASTRO A., ARRIBA, PEDREIRA J., BARREIRO P., GÁRCIA-SAMANIEGO J., MARTIN-CARBONERO L., JIMENEZ-NACHER I., SORIANO V. Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS, 2003, 17: 1023-1028.
68. LAGUNO M., MURILLAS J., BLANCO J.L., MARTINEZ E., MIQUEL R., SANCHEZ-TAPIAS J.M., BARGALLO X., GARCIA-CRIADO A., DE LAZZARI E., LARROUSSE M., LEO A., LONCA M., MILINCOVIC A., GATELL J.M., MALLOLAS J. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS, 2004, 18: F27-F36.
69. CARRAT F, BANI-SADR F, POL S, ROSENTHAL E, LUNEL-FABIANI F, BENZEKRI A, MORAND P, GOUJARD C, PIALOUX G, PIROTH L, SALMON-CERON D, DEGOTT C, CACOUB P, PERRONNE C, ANRS HCO2 RIBAVIC STUDY TEAM. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA. 2004, 292: 2839-2848.
70. CHUNG R.T., ANDERSEN J., VOLBERDING P., ROBBINS G.K., LIU T., SHERMAN K.E., PETERS M.G., KOZIEL M.J., BHAN A.K., ALSTON B., COLQUHOUN D., NEVIN T., HARB G., VAN DER HORST C, The AIDS Clinical Trials Group A507I Study Team. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N. Engl. J. Med., 2004, 351: 451-459.
71. TORRIANI F.J., RODIGUEZ-TORRES M., ROCKSTROH J.K., LISSEN E., GONZALEZ-GARCIA J., LAZZARIN A., CAROSI G., SASADEUSZ J., KATLAMA C., MONTANER J., SETTE H. JR., PASSE S., DE PAMPHILIS J., DUFF F., SCHRENCK U.M., DIETERICH D.T., The APRICOT Study Group. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N. Engl. J. Med., 2004, 351: 438-450.
72. DAVIS G.L., WONG J.B., McHUTCHISON J.G., MANNS M.P., HARVEY J., ALBRECHT J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology, 2003, 38: 645-652.
73. SORIANO V., PUOTI M., SULKOWSKI M., MAUSS S., CACOUB P., CARGNEL A., DIETERICH D., HATZAKIS A., ROCKSTROH J. Care of patients with hepatitis C and HIV co-infection. AIDS, 2004, 18: 1-12.
74. NELSON M.R., MATTHEWS G., BROOK M.G., MAIN J., The British HIV association. BHIVA guidelines: coinfection with HIV and chronic hepatitis C virus. HIV Medicine, 2003, 4: 52-62.
75. RUYS T.A., REESINK H.W., LANGE J.M.A. Coinfectie met hepatitis-C-virus en HIV. Ned. Tijdschr. Geneesk., 2003, 147: 2056-2060.
76. STRADER D.B., WRIGHT T., THOMAS D.L., SEEFF L.B. Diagnosis, management, and treatment of hepatitis C. Hepatology, 2004, 39: 1147-71.